Tart Cherry Juice for Paclitaxel-Induced Neuropathy
This study is looking at whether tart cherry juice can help prevent nerve damage (neuropathy) in people with breast or ovarian cancer who are receiving paclitaxel chemotherapy. Researchers want to see if drinking tart cherry juice, either a high dose or a low dose, can reduce this common side effect. You might be able to join if you have Stage I, II, III, or IV breast or ovarian cancer and are planning to receive paclitaxel chemotherapy. The study will measure how well tart cherry juice prevents nerve damage over a period of up to one year. The current recruitment status is unclear.
- Study design
- This is a randomized study comparing two different doses of tart cherry juice, with 86 planned participants.
- What's involved
- You would drink tart cherry juice twice daily for up to 14 weeks, starting within 7 days of your chemotherapy. You will have follow-up visits after chemotherapy and at 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to one year after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06268665
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Recruiting
PHASE2Ages 18+InterventionalTreatmentUniversity of California, DavisInvestigator-initiated
~86 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:Tart Cherry Juice
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy of tart cherry juice supplementation in the prevention of paclitaxel-induced peripheral neuropathy (PIPN) in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy.
Measured over Up to 1 year.
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Eve Rodler, MD · PRINCIPAL_INVESTIGATOR · University of California, Davis
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria.
Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment.
Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed.
Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed.
Concurrent use of immune checkpoint inhibitor therapy is allowed.
(Neo)adjuvant chemotherapy with doxorubicin and cyclophosphamide is allowed.
Concurrent use of carboplatin with weekly paclitaxel in the study is allowed.
May participate concurrently in other cancer trials.
Must be able to complete questionnaires in English or Spanish.
Age ≥ 18 years old at the time of consent.
ECOG performance status of 0 - 1 (Karnofsky scale ≥ 70%, see Appendix).
Ability to understand and the willingness to sign a written informed consent document.
Individuals of child-bearing potential must agree to use birth control (e.g., hormonal or barrier method; abstinence, an intrauterine device) prior - to study entry, for the duration of study participation (including dose interruptions), and for 3 months after the last dose of tart cherry juice supplement; or be surgically sterilized (e.g., hysterectomy or tubal ligation).
Patients with known human immunodeficiency virus (HIV) are allowed in the study, but HIV-positive patients must have:
A stable regimen of highly active anti-retroviral therapy (HAART)
No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
A CD4 count above 250 cells/µL and an undetectable HIV viral load on standard PCR-based tests within the last year.
Stated willingness to not drink any additional tart cherry or any cherry juice while on the study.
Ability and willingness to adhere to the study visit schedule and other protocol requirements
Exclusion
Have received any prior therapy with taxanes, vinca alkaloids, eribulin, ixabepilone, or platinum. Doxorubicin is allowed (≥ 2 week washout period required).
Active or history of peripheral neuropathy, or any chronic diseases associated with peripheral neuropathy such as diabetes mellitus, alcohol use disorder, or systemic lupus erythematosus.
Currently taking anticoagulant medication.
Currently taking Vitamin E, glutamine, alpha lipoic acid, gabapentin, nortriptyline, amitriptyline or duloxetine. If a patient is taking any of these supplements/medications, they must agree to stop at the time of registration. Multivitamins containing Vitamin E are allowed, however Vitamin E \> 1,000 international units (IU) must be discontinued at the time of registration.
Patients may not use cold therapy gloves for chemotherapy induced neuropathy.
Known allergy to cherries.
Inability to swallow liquid.
Pregnant or breastfeeding individuals (lactating individuals must agree not to breast feed while taking study juice supplementation).
Any condition that would prohibit the understanding or rendering of informed consent.
Any condition that in the opinion of the investigator would interfere with safety or compliance while on trial.
What this trial measures
- Efficacy of tart cherry juice supplementation in the prevention of paclitaxel-induced peripheral neuropathy (PIPN) in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy.Up to 1 year.
Number of participants between study arms experiencing PIPN using the 11-item peripheral neuropathy component of the Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane) survey.